Does vitamin C deficiency promote fatty liver disease development?

Nutrients

Volumn 6, Issue 12, 2014, Pages 5473-5499

  Ipsen, David Højland ^a   Tveden Nyborg, Pernille ^a   Lykkesfeldt, Jens ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antioxidants; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Obesity; Oxidative stress; Reactive oxygen species; Vitamin C; Vitamin C deficiency

Indexed keywords

ADIPONECTIN; ASCORBIC ACID; CHOLESTEROL; FATTY ACID; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ASCORBIC ACID DEFICIENCY; DIETARY INTAKE; DISEASE COURSE; DYSLIPIDEMIA; FOOD FREQUENCY QUESTIONNAIRE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTERVENTION STUDY; LIPID STORAGE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; ANIMAL; BLOOD; COMORBIDITY; LIFESTYLE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ADIPOSITY; ANIMALS; ASCORBIC ACID; ASCORBIC ACID DEFICIENCY; BIOMARKERS; COMORBIDITY; HUMANS; INFLAMMATION; LIFE STYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITIONAL STATUS; OBESITY; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84914698446     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu6125473     Document Type: Review

References (129)

1. Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; Mullany, E.C.; Biryukov, S.; Abbafati, C.; Abera, S.F.; et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the global burden of disease study 2013. Lancet 2014, 384, 766-781.
2. Bastard, J.P.; Maachi, M.; Lagathu, C.; Kim, M.J.; Caron, M.; Vidal, H.; Capeau, J.; Feve, B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006, 17, 4-12.
3. Jankovic, A.; Korac, A.; Srdic-Galic, B.; Buzadzic, B.; Otasevic, V.; Stancic, A.; Vucetic, M.; Markelic, M.; Velickovic, K.; Golic, I.; et al. Differences in the redox status of human visceral and subcutaneous adipose tissues-Relationships to obesity and metabolic risk. Metabolism 2014, 63, 661-671.
4. Uzun, H.; Zengin, K.; Taskin, M.; Aydin, S.; Simsek, G.; Dariyerli, N. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic swedish adjustable gastric banding. Obes. Surg. 2004, 14, 659-665.
5. Mathieu, P.; Lemieux, I.; Despres, J.P. Obesity, inflammation, and cardiovascular risk. Clin. Pharmacol. Ther. 2010, 87, 407-416.
6. Qureshi, K.; Abrams, G.A. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J. Gastroenterol. 2007, 13, 3540-3553.
7. Tilg, H.; Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010, 52, 1836-1846.
8. Horoz, M.; Bolukbas, C.; Bolukbas, F.F.; Sabuncu, T.; Aslan, M.; Sarifakiogullari, S.; Gunaydin, N.; Erel, O. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol. 2005, 5, 35.
9. Da Silva, V.R.; Moreira, E.A.; Wilhelm-Filho, D.; de Miranda, J.X.; Beninca, J.P.; Vigil, S.V.; Moratelli, A.M.; Garlet, T.R.; de Souza Meirelles, M.S.; Vannucchi, H.; et al. Proinflammatory and oxidative stress markers in patients submitted to roux-en-y gastric bypass after 1 year of follow-up. Eur. J. Clin. Nutr. 2012, 66, 891-899.
10. Buettner, G.R. The pecking order of free radicals and antioxidants: Lipid peroxidation, α-tocopherol, and ascorbate. Arch. Biochem. Biophys. 1993, 300, 535-543.
11. Kivirikko, K.I.; Myllyla, R. Post-translational processing of procollagens. Ann. N. Y. Acad. Sci. 1985, 460, 187-201.
12. Smith, J.L.; Hodges, R.E. Serum levels of vitamin C in relation to dietary and supplemental intake of vitamin C in smokers and nonsmokers. Ann. N. Y. Acad. Sci. 1987, 498, 144-152.
13. Simon, J.A.; Hudes, E.S.; Tice, J.A. Relation of serum ascorbic acid to mortality among us adults. J. Am. Coll. Nutr. 2001, 20, 255-263.
14. Hampl, J.S.; Taylor, C.A.; Johnston, C.S. Vitamin C deficiency and depletion in the United States: The third national health and nutrition examination survey, 1988 to 1994. Am. J. Public Health 2004, 94, 870-875.
15. Wrieden, W.L.; Hannah, M.K.; Bolton-Smith, C.; Tavendale, R.; Morrison, C.; Tunstall-Pedoe, H. Plasma vitamin C and food choice in the third glasgow monica population survey. J. Epidemiol. Commun. Health 2000, 54, 355-360.
16. Lykkesfeldt, J.; Poulsen, H.E. Is vitamin C supplementation beneficial? Lessons learned from randomised controlled trials. Br. J. Nutr. 2010, 103, 1251-1259.
17. Frei, B.; Birlouez-Aragon, I.; Lykkesfeldt, J. Authors' perspective: What is the optimum intake of vitamin C in humans? Crit. Rev. Food Sci. Nutr. 2012, 52, 815-829.
18. Tveden-Nyborg, P.; Lykkesfeldt, J. Does vitamin C deficiency increase lifestyle-associated vascular disease progression? Evidence based on experimental and clinical studies. Antioxid. Redox Signal. 2013, 19, 2084-2104.
19. Aasheim, E.T.; Hofso, D.; Hjelmesaeth, J.; Birkeland, K.I.; Bohmer, T. Vitamin status in morbidly obese patients: A cross-sectional study. Am. J. Clin. Nutr. 2008, 87, 362-369.
20. Canoy, D.; Wareham, N.; Welch, A.; Bingham, S.; Luben, R.; Day, N.; Khaw, K.T. Plasma ascorbic acid concentrations and fat distribution in 19,068 british men and women in the european prospective investigation into cancer and nutrition norfolk cohort study. Am. J. Clin. Nutr. 2005, 82, 1203-1209.
21. Johnston, C.S.; Beezhold, B.L.; Mostow, B.; Swan, P.D. Plasma vitamin C is inversely related to body mass index and waist circumference but not to plasma adiponectin in nonsmoking adults. J. Nutr. 2007, 137, 1757-1762.
22. Mah, E.; Matos, M.D.; Kawiecki, D.; Ballard, K.; Guo, Y.; Volek, J.S.; Bruno, R.S. Vitamin C status is related to proinflammatory responses and impaired vascular endothelial function in healthy, college-aged lean and obese men. J. Am. Diet. Assoc. 2011, 111, 737-743.
23. Sun, K.; Kusminski, C.M.; Scherer, P.E. Adipose tissue remodeling and obesity. J. Clin. Investig. 2011, 121, 2094-2101.
24. Bano, G. Glucose homeostasis, obesity and diabetes. Best Pract. Res. Clin. Obstet. Gynaecol. 2013, 27, 715-726.
25. Furukawa, S.; Fujita, T.; Shimabukuro, M.; Iwaki, M.; Yamada, Y.; Nakajima, Y.; Nakayama, O.; Makishima, M.; Matsuda, M.; Shimomura, I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Investig. 2004, 114, 1752-1761.
26. Odegaard, J.I.; Chawla, A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013, 339, 172-177.
27. Stumvoll, M.; Goldstein, B.J.; van Haeften, T.W. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 2005, 365, 1333-1346.
28. Wisse, B.E. The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 2004, 15, 2792-2800.
29. Sabio, G.; Das, M.; Mora, A.; Zhang, Z.; Jun, J.Y.; Ko, H.J.; Barrett, T.; Kim, J.K.; Davis, R.J. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322, 1539-1543.
30. Farnier, C.; Krief, S.; Blache, M.; Diot-Dupuy, F.; Mory, G.; Ferre, P.; Bazin, R. Adipocyte functions are modulated by cell size change: Potential involvement of an integrin/erk signalling pathway. Int. J. Obes. Relat. Metab. Disord. 2003, 27, 1178-1186.
31. Mittelman, S.D.; van Citters, G.W.; Kirkman, E.L.; Bergman, R.N. Extreme insulin resistance of the central adipose depot in vivo. Diabetes 2002, 51, 755-761.
32. Nguyen, M.T.; Favelyukis, S.; Nguyen, A.K.; Reichart, D.; Scott, P.A.; Jenn, A.; Liu-Bryan, R.; Glass, C.K.; Neels, J.G.; Olefsky, J.M. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 2007, 282, 35279-35292.
33. Elnakish, M.T.; Hassanain, H.H.; Janssen, P.M.; Angelos, M.G.; Khan, M. Emerging role of oxidative stress in metabolic syndrome and cardiovascular diseases: Important role of rac/nadph oxidase. J. Pathol. 2013, 231, 290-300.
34. Ford, E.S.; Mokdad, A.H.; Giles, W.H.; Brown, D.W. The metabolic syndrome and antioxidant concentrations: Findings from the third national health and nutrition examination survey. Diabetes 2003, 52, 2346-2352.
35. Lissner, L.; Lindroos, A.K.; Sjostrom, L. Swedish obese subjects (SOS): An obesity intervention study with a nutritional perspective. Eur. J. Clin. Nutr. 1998, 52, 316-322.
36. Del Mar Bibiloni, M.; Maffeis, C.; Llompart, I.; Pons, A.; Tur, J.A. Dietary factors associated with subclinical inflammation among girls. Eur. J. Clin. Nutr. 2013, 67, 1264-1270.
37. Rose, F.J.; Webster, J.; Barry, J.B.; Phillips, L.K.; Richards, A.A.; Whitehead, J.P. Synergistic effects of ascorbic acid and thiazolidinedione on secretion of high molecular weight adiponectin from human adipocytes. Diabetes Obes. Metab. 2010, 12, 1084-1089.
38. Afkhami-Ardekani, M.; Shojaoddiny-Ardekani, A. Effect of vitamin C on blood glucose, serum lipids & serum insulin in type 2 diabetes patients. Indian J. Med. Res. 2007, 126, 471-474.
39. Soares, A.F.; Guichardant, M.; Cozzone, D.; Bernoud-Hubac, N.; Bouzaidi-Tiali, N.; Lagarde, M.; Geloen, A. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic. Biol. Med. 2005, 38, 882-889.
40. Hui, J.M.; Hodge, A.; Farrell, G.C.; Kench, J.G.; Kriketos, A.; George, J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 2004, 40, 46-54.
41. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american gastroenterological association, american association for the study of liver diseases, and american college of gastroenterology. Gastroenterology 2012, 142, 1592-1609.
42. Bechmann, L.P.; Hannivoort, R.A.; Gerken, G.; Hotamisligil, G.S.; Trauner, M.; Canbay, A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J. Hepatol. 2012, 56, 952-964.
43. Hebbard, L.; George, J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 35-44.
44. Adams, L.A.; Sanderson, S.; Lindor, K.D.; Angulo, P. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005, 42, 132-138.
45. Ekstedt, M.; Franzen, L.E.; Mathiesen, U.L.; Thorelius, L.; Holmqvist, M.; Bodemar, G.; Kechagias, S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44, 865-873.
46. Bugianesi, E.; Leone, N.; Vanni, E.; Marchesini, G.; Brunello, F.; Carucci, P.; Musso, A.; de Paolis, P.; Capussotti, L.; Salizzoni, M.; et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123, 134-140.
47. Angelico, F.; del Ben, M.; Conti, R.; Francioso, S.; Feole, K.; Fiorello, S.; Cavallo, M.G.; Zalunardo, B.; Lirussi, F.; Alessandri, C.; et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2005, 90, 1578-1582.
48. Marchesini, G.; Bugianesi, E.; Forlani, G.; Cerrelli, F.; Lenzi, M.; Manini, R.; Natale, S.; Vanni, E.; Villanova, N.; Melchionda, N.; et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37, 917-923.
49. Luyckx, F.H.; Desaive, C.; Thiry, A.; Dewe, W.; Scheen, A.J.; Gielen, J.E.; Lefebvre, P.J. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. Int. J. Obes. Relat. Metab. Disord. 1998, 22, 222-226.
50. Mohan, V.; Farooq, S.; Deepa, M.; Ravikumar, R.; Pitchumoni, C.S. Prevalence of non-alcoholic fatty liver disease in urban south indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res. Clin. Pract. 2009, 84, 84-91.
51. Abdelmalek, M.F.; Diehl, A.M. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med. Clin. N. Am. 2007, 91, 1125-1149.
52. Gaggini, M.; Morelli, M.; Buzzigoli, E.; deFronzo, R.A.; Bugianesi, E.; Gastaldelli, A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013, 5, 1544-1560.
53. Donnelly, K.L.; Smith, C.I.; Schwarzenberg, S.J.; Jessurun, J.; Boldt, M.D.; Parks, E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Investig. 2005, 115, 1343-1351.
54. Bardini, G.; Rotella, C.M.; Giannini, S. Dyslipidemia and diabetes: Reciprocal impact of impaired lipid metabolism and beta-cell dysfunction on micro- and macrovascular complications. Rev. Diabet. Stud. 2012, 9, 82-93.
55. McRae, M.P. Vitamin C supplementation lowers serum low-density lipoprotein cholesterol and triglycerides: A meta-analysis of 13 randomized controlled trials. J. Chiropr. Med. 2008, 7, 48-58.
56. Moschen, A.R.; Molnar, C.; Geiger, S.; Graziadei, I.; Ebenbichler, C.F.; Weiss, H.; Kaser, S.; Kaser, A.; Tilg, H. Anti-inflammatory effects of excessive weight loss: Potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 2010, 59, 1259-1264.
57. Kamada, Y.; Tamura, S.; Kiso, S.; Matsumoto, H.; Saji, Y.; Yoshida, Y.; Fukui, K.; Maeda, N.; Nishizawa, H.; Nagaretani, H.; et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003, 125, 1796-1807.
58. Finelli, C.; Tarantino, G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J. Gastroenterol. 2013, 19, 802-812.
59. Kim, J.Y.; van de Wall, E.; Laplante, M.; Azzara, A.; Trujillo, M.E.; Hofmann, S.M.; Schraw, T.; Durand, J.L.; Li, H.; Li, G.; et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Investig. 2007, 117, 2621-2637.
60. Park, E.J.; Lee, J.H.; Yu, G.Y.; He, G.; Ali, S.R.; Holzer, R.G.; Osterreicher, C.H.; Takahashi, H.; Karin, M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing Il-6 and TNF expression. Cell 2010, 140, 197-208.
61. Tappy, L.; Le, K.A. Does fructose consumption contribute to non-alcoholic fatty liver disease? Clin. Res. Hepatol. Gastroenterol. 2012, 36, 554-560.
62. Podszun, M.C.; Grebenstein, N.; Spruss, A.; Schlueter, T.; Kremoser, C.; Bergheim, I.; Frank, J. Dietary α-tocopherol and atorvastatin reduce high-fat-induced lipid accumulation and down-regulate cd36 protein in the liver of guinea pigs. J. Nutr. Biochem. 2014, 25, 573-579.
63. Ye, P.; Cheah, I.K.; Halliwell, B. A high-fat and cholesterol diet causes fatty liver in guinea pigs. The role of iron and oxidative damage. Free Radic. Res. 2013, 47, 602-613.
64. Coban, J.; Evran, B.; Ozkan, F.; Cevik, A.; Dogru-Abbasoglu, S.; Uysal, M. Effect of blueberry feeding on lipids and oxidative stress in the serum, liver and aorta of guinea pigs fed on a high-cholesterol diet. Biosci. Biotechnol. Biochem. 2013, 77, 389-391.
65. Kim, J.E.; Clark, R.M.; Park, Y.; Lee, J.; Fernandez, M.L. Lutein decreases oxidative stress and inflammation in liver and eyes of guinea pigs fed a hypercholesterolemic diet. Nutr. Res. Pract. 2012, 6, 113-119.
66. Mari, M.; Caballero, F.; Colell, A.; Morales, A.; Caballeria, J.; Fernandez, A.; Enrich, C.; Fernandez-Checa, J.C.; Garcia-Ruiz, C. Mitochondrial free cholesterol loading sensitizes to TNF- and FAS-mediated steatohepatitis. Cell Metab. 2006, 4, 185-198.
67. Feldstein, A.E.; Werneburg, N.W.; Canbay, A.; Guicciardi, M.E.; Bronk, S.F.; Rydzewski, R.; Burgart, L.J.; Gores, G.J. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway. Hepatology 2004, 40, 185-194.
68. Basaranoglu, M.; Basaranoglu, G.; Senturk, H. From fatty liver to fibrosis: A tale of "second hit". World J. Gastroenterol. 2013, 19, 1158-1165.
69. Pessayre, D. Role of mitochondria in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2007, 22, S20-S27.
70. Wei, Y.; Wang, D.; Topczewski, F.; Pagliassotti, M.J. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am. J. Physiol. Endocrinol. Metab. 2006, 291, E275-E281.
71. Van Rooyen, D.M.; Larter, C.Z.; Yeh, M.M.; Haigh, W.G.; Teoh, N.; Farrell, G.C. Ezetimibe and atorvastatin ameliorate liver injury in foz/foz mice with NASH. J. Gastroenterol. Hepatol. 2011, 26, 2-14.
72. Fujii, H.; Kawada, N. Inflammation and fibrogenesis in steatohepatitis. J. Gastroenterol. 2012, 47, 215-225.
73. Laurent, A.; Nicco, C.; Tran van Nhieu, J.; Borderie, D.; Chereau, C.; Conti, F.; Jaffray, P.; Soubrane, O.; Calmus, Y.; Weill, B.; et al. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology 2004, 39, 1277-1285.
74. Farrell, G.C.; van Rooyen, D.; Gan, L.; Chitturi, S. Nash is an inflammatory disorder: Pathogenic, prognostic and therapeutic implications. Gut Liver 2012, 6, 149-171.
75. Narasimhan, S.; Gokulakrishnan, K.; Sampathkumar, R.; Farooq, S.; Ravikumar, R.; Mohan, V.; Balasubramanyam, M. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin. Biochem. 2010, 43, 815-821.
76. Valdecantos, M.P.; Perez-Matute, P.; Quintero, P.; Martinez, J.A. Vitamin C, resveratrol and lipoic acid actions on isolated rat liver mitochondria: All antioxidants but different. Redox Rep. 2010, 15, 207-216.
77. Musso, G.; Gambino, R.; de Michieli, F.; Cassader, M.; Rizzetto, M.; Durazzo, M.; Faga, E.; Silli, B.; Pagano, G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37, 909-916.
78. Ferolla, S.M.; Ferrari, T.C.; Lima, M.L.; Reis, T.O.; Tavares, W.C., Jr.; Couto, O.F.; Vidigal, P.V.; Fausto, M.A.; Couto, C.A. Dietary patterns in brazilian patients with nonalcoholic fatty liver disease: A cross-sectional study. Clinics 2013, 68, 11-17.
79. Koruk, M.; Taysi, S.; Savas, M.C.; Yilmaz, O.; Akcay, F.; Karakok, M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann. Clin. Lab. Sci. 2004, 34, 57-62.
80. Videla, L.A.; Rodrigo, R.; Orellana, M.; Fernandez, V.; Tapia, G.; Quinones, L.; Varela, N.; Contreras, J.; Lazarte, R.; Csendes, A.; et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. 2004, 106, 261-268.
81. Frikke-Schmidt, H.; Lykkesfeldt, J. Role of marginal vitamin C deficiency in atherogenesis: In vivo models and clinical studies. Basic Clin. Pharmacol. Toxicol. 2009, 104, 419-433.
82. Roomi, M.W. Association between hyperlipidemia and hepatic cytochrome p-450 in guinea pigs. Res. Commun. Mol. Pathol. Pharmacol. 1997, 97, 139-150.
83. Montano, C.E.; Fernandez, M.L.; McNamara, D.J. Regulation of apolipoprotein B-containing lipoproteins by vitamin C level and dietary fat saturation in guinea pigs. Metabolism 1998, 47, 883-891.
84. Ginter, E.; Cerven, J.; Nemec, R.; Mikus, L. Lowered cholesterol catabolism in guinea pigs with chronic ascorbic acid deficiency. Am. J. Clin. Nutr. 1971, 24, 1238-1245.
85. Ginter, E. Ascorbic acid in cholesterol and bile acid metabolism. Ann. N. Y. Acad. Sci. 1975, 258, 410-421.
86. Sharma, P.; Pramod, J.; Sharma, P.K.; Sapra, M.; Manorma; Kothari, L.K. Effect of vitamin C deficiency and excess on the liver: A histopathological and biochemical study in guinea pigs fed normal or high cholesterol diet. Indian J. Pathol. Microbiol. 1990, 33, 307-313.
87. Frikke-Schmidt, H.; Tveden-Nyborg, P.; Birck, M.M.; Lykkesfeldt, J. High dietary fat and cholesterol exacerbates chronic vitamin C deficiency in guinea pigs. Br. J. Nutr. 2011, 105, 54-61.
88. Horio, F.; Ozaki, K.; Oda, H.; Makino, S.; Hayashi, Y.; Yoshida, A. Effect of dietary ascorbic acid, cholesterol and PCB on cholesterol concentrations in serum and liver in a rat mutant unable to synthesize ascorbic acid. J. Nutr. 1987, 117, 1036-1044.
89. Uchida, K.; Nomura, Y.; Takase, H.; Tasaki, T.; Seo, S.; Hayashi, Y.; Takeuchi, N. Effect of vitamin C depletion on serum cholesterol and lipoprotein levels in ODS (od/od) rats unable to synthesize ascorbic acid. J. Nutr. 1990, 120, 1140-1147.
90. Fernandez, M.L. Guinea pigs as models for cholesterol and lipoprotein metabolism. J. Nutr. 2001, 131, 10-20.
91. Yang, R.; Guo, P.; Song, X.; Liu, F.; Gao, N. Hyperlipidemic guinea pig model: Mechanisms of triglyceride metabolism disorder and comparison to rat. Biol. Pharm. Bull. 2011, 34, 1046-1051.
92. Barja, G.; Lopez-Torres, M.; Perez-Campo, R.; Rojas, C.; Cadenas, S.; Prat, J.; Pamplona, R. Dietary vitamin C decreases endogenous protein oxidative damage, malondialdehyde, and lipid peroxidation and maintains fatty acid unsaturation in the guinea pig liver. Free Radic. Biol. Med. 1994, 17, 105-115.
93. Mori, T.; Kitamura, R.; Imaoka, S.; Funae, Y.; Kitada, M.; Kamataki, T. Examination for lipid peroxidation in liver microsomes of guinea pigs as a causal factor in the decrease in the content of cytochrome p-450 due to ascorbic acid deficiency. Res. Commun. Chem. Pathol. Pharmacol. 1992, 75, 209-219.
94. Amano, A.; Sato, Y.; Kishimoto, Y.; Takahashi, K.; Handa, S.; Aigaki, T.; Maruyama, N.; Ishigami, A. Effects of ascorbic acid deficiency on protein and lipid oxidation in livers from SMP30/GNL knockout mice. J. Nutr. Sci. Vitaminol. 2013, 59, 489-495.
95. Pierce, M.R.; Diasio, D.L.; Rodrigues, L.M.; Harrison, F.E.; May, J.M. Combined vitamin C and E deficiency induces motor defects in gulo(-/-)/SVCT2(+/-) mice. Nutr. Neurosci. 2013, 16, 160-173.
96. Harrison, F.E.; Meredith, M.E.; Dawes, S.M.; Saskowski, J.L.; May, J.M. Low ascorbic acid and increased oxidative stress in gulo(-/-) mice during development. Brain Res. 2010, 1349, 143-152.
97. Horio, F.; Kiyama, K.; Kobayashi, M.; Kawai, K.; Tsuda, T. Ascorbic acid deficiency stimulates hepatic expression of inflammatory chemokine, cytokine-induced neutrophil chemoattractant-1, in scurvy-prone ODS rats. J. Nutr. Sci. Vitaminol. 2006, 52, 28-32.
98. Al-Serri, A.; Anstee, Q.M.; Valenti, L.; Nobili, V.; Leathart, J.B.; Dongiovanni, P.; Patch, J.; Fracanzani, A.; Fargion, S.; Day, C.P.; et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. J. Hepatol. 2012, 56, 448-454.
99. Seki, S.; Kitada, T.; Yamada, T.; Sakaguchi, H.; Nakatani, K.; Wakasa, K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 2002, 37, 56-62.
100. Rezazadeh, A.; Yazdanparast, R.; Molaei, M. Amelioration of diet-induced nonalcoholic steatohepatitis in rats by Mn-salen complexes via reduction of oxidative stress. J. Biomed. Sci. 2012, 19, 26.
101. Rezazadeh, A.; Yazdanparast, R. Prevention of nonalcoholic steatohepatitis in rats by two manganese-salen complexes. Iran. Biomed. J. 2014, 18, 41-48.
102. Oliveira, C.P.; Gayotto, L.C.; Tatai, C.; Della Nina, B.I.; Lima, E.S.; Abdalla, D.S.; Lopasso, F.P.; Laurindo, F.R.; Carrilho, F.J. Vitamin C and vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats. Nutr. J. 2003, 2, 9.
103. Nambisan, B.; Kurup, P.A. Ascorbic acid and glycosaminoglycan and lipid metabolism in guinea pigs fed normal and atherogenic diets. Atherosclerosis 1975, 22, 447-461.
104. Hathcock, J.N.; Azzi, A.; Blumberg, J.; Bray, T.; Dickinson, A.; Frei, B.; Jialal, I.; Johnston, C.S.; Kelly, F.J.; Kraemer, K.; et al. Vitamins E and C are safe across a broad range of intakes. Am. J. Clin. Nutr. 2005, 81, 736-745.
105. The National Academies. Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids; The National Academies Press: Washington, DC, USA, 2000.
106. Monsen, E.R. Dietary reference intakes for the antioxidant nutrients: Vitamin C, vitamin E, selenium, and carotenoids. J. Am. Diet. Assoc. 2000, 100, 637-640.
107. Johnson, R.K. Dietary intake-How do we measure what people are really eating? Obes. Res. 2002, 10, 63s-68s.
108. Han, J.M.; Jo, A.N.; Lee, S.M.; Bae, H.S.; Jun, D.W.; Cho, Y.K.; Suk, K.T.; Yoon, J.H.; Ahn, S.B.; Cho, Y.J.; et al. Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among korean adults. J. Gastroenterol. Hepatol. 2014, 29, 1265-1272.
109. Vos, M.B.; Colvin, R.; Belt, P.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Schwimmer, J.B.; Tonascia, J.; Unalp, A.; Lavine, J.E. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J. Pediatr. Gastroenterol. Nutr. 2012, 54, 90-96.
110. Mager, D.R.; Patterson, C.; So, S.; Rogenstein, C.D.; Wykes, L.J.; Roberts, E.A. Dietary and physical activity patterns in children with fatty liver. Eur. J. Clin. Nutr. 2010, 64, 628-635.
111. Da Silva, H.E.; Arendt, B.M.; Noureldin, S.A.; Therapondos, G.; Guindi, M.; Allard, J.P. A cross-sectional study assessing dietary intake and physical activity in canadian patients with nonalcoholic fatty liver disease vs. healthy controls. J. Acad. Nutr. Diet. 2014, 114, 1181-1194.
112. Madan, K.; Bhardwaj, P.; Thareja, S.; Gupta, S.D.; Saraya, A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J. Clin. Gastroenterol. 2006, 40, 930-935.
113. Canbakan, B.; Senturk, H.; Tahan, V.; Hatemi, I.; Balci, H.; Toptas, T.; Sonsuz, A.; Velet, M.; Aydin, S.; Dirican, A.; et al. Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease. Acta Gastro-Enterol. Belgica 2007, 70, 277-284.
114. Dehghan, M.; Akhtar-Danesh, N.; McMillan, C.R.; Thabane, L. Is plasma vitamin C an appropriate biomarker of vitamin C intake? A systematic review and meta-analysis. Nutr. J. 2007, 6, 41.
115. Levine, M.; Conry-Cantilena, C.; Wang, Y.; Welch, R.W.; Washko, P.W.; Dhariwal, K.R.; Park, J.B.; Lazarev, A.; Graumlich, J.F.; King, J.; et al. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. USA 1996, 93, 3704-3709.
116. Pfister, R.; Sharp, S.J.; Luben, R.; Wareham, N.J.; Khaw, K.T. Plasma vitamin C predicts incident heart failure in men and women in european prospective investigation into cancer and nutrition-norfolk prospective study. Am. Heart J. 2011, 162, 246-253.
117. Nobili, V.; Manco, M.; Devito, R.; Ciampalini, P.; Piemonte, F.; Marcellini, M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006, 24, 1553-1561.
118. Nobili, V.; Manco, M.; Devito, R.; di Ciommo, V.; Comparcola, D.; Sartorelli, M.R.; Piemonte, F.; Marcellini, M.; Angulo, P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology 2008, 48, 119-128.
119. Harrison, S.A.; Torgerson, S.; Hayashi, P.; Ward, J.; Schenker, S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2003, 98, 2485-2490.
120. Adams, L.A.; Angulo, P. Vitamins E and C for the treatment of NASH: Duplication of results but lack of demonstration of efficacy. Am. J. Gastroenterol. 2003, 98, 2348-2350.
121. Piñeiro-Carrero, V.M.; Piñeiro, E.O. Liver. Pediatrics 2004, 113, 1097-1106.
122. Papandreou, D.; Rousso, I.; Mavromichalis, I. Update on non-alcoholic fatty liver disease in children. Clin. Nutr. 2007, 26, 409-415.
123. Kawanaka, M.; Nishino, K.; Nakamura, J.; Suehiro, M.; Goto, D.; Urata, N.; Oka, T.; Kawamoto, H.; Nakamura, H.; Yodoi, J.; et al. Treatment of nonalcoholic steatohepatitis with vitamins E and C: A pilot study. Hepat. Med. 2013, 5, 11-16.
124. Ersöz, G.; Gunsar, F.; Karasu, Z.; Akay, S.; Batur, Y.; Akarca, U.S. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turkish J. Gastroenterol. 2005, 16, 124-128.
125. Foster, T.; Budoff, M.J.; Saab, S.; Ahmadi, N.; Gordon, C.; Guerci, A.D. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St. Francis Heart Study randomized clinical trial. Am. J. Gastroenterol. 2011, 106, 71-77.
126. Targher, G.; Bertolini, L.; Rodella, S.; Lippi, G.; Franchini, M.; Zoppini, G.; Muggeo, M.; Day, C.P. Nash predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity 2008, 16, 1394-1399.
127. Speliotes, E.K.; Massaro, J.M.; Hoffmann, U.; Vasan, R.S.; Meigs, J.B.; Sahani, D.V.; Hirschhorn, J.N.; O'Donnell, C.J.; Fox, C.S. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The framingham heart study. Hepatology 2010, 51, 1979-1987.
128. Hatzitolios, A.; Savopoulos, C.; Lazaraki, G.; Sidiropoulos, I.; Haritanti, P.; Lefkopoulos, A.; Karagiannopoulou, G.; Tzioufa, V.; Dimitrios, K. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J. Gastroenterol. 2004, 23, 131-134.
129. Saadeh, S.; Younossi, Z.M.; Remer, E.M.; Gramlich, T.; Ong, J.P.; Hurley, M.; Mullen, K.D.; Cooper, J.N.; Sheridan, M.J. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123, 745-750.